Original data (with adjusted standard errors for multi-arm studies):

              treat1      treat2      TE   seTE seTE.adj.f seTE.adj.r narms multiarm
4           BZD-long   BZD-short -0.3034 0.2576     0.2576     0.3056     2         
5            placebo    zolpidem -0.4505 0.1385     0.2224     0.2801     3        *
5           zaleplon    zolpidem -0.1712 0.1104     0.1223     0.2349     3        *
5            placebo    zaleplon -0.2793 0.1142     0.1279     0.2393     3        *
6        eszopiclone     placebo  0.4040 0.1026     0.1026     0.1938     2         
9          BZD-short   zopiclone  0.2617 0.2826     0.2826     0.3269     2         
24         BZD-short     placebo  1.1829 0.3131     0.3131     0.3537     2         
32           placebo    zaleplon  0.0294 0.1195     0.1369     0.2429     3        *
32          zaleplon    zolpidem -0.3039 0.1235     0.1439     0.2480     3        *
32           placebo    zolpidem -0.2745 0.1402     0.1978     0.2760     3        *
34           placebo   zopiclone -0.7932 0.0971     0.0971     0.1909     2         
36  BZD-intermediate     placebo  0.7540 0.1612     0.1612     0.2303     2         
44  BZD-intermediate     placebo  1.3538 0.2862     0.2862     0.3301     2         
48          zaleplon    zolpidem -0.1046 0.1337     0.1337     0.2119     2         
50  BZD-intermediate    zolpidem -0.6721 0.3211     0.3211     0.3608     2         
60           doxepin     placebo  0.4235 0.1788     0.1788     0.2429     2         
70         melatonin     placebo -0.5156 0.3214     0.3214     0.3610     2         
72          BZD-long   BZD-short -0.0000 0.4082     0.5000     0.5390     3        *
72         BZD-short     placebo  0.0000 0.4082     0.5000     0.5390     3        *
72          BZD-long     placebo  0.0000 0.4082     0.5000     0.5390     3        *
73          BZD-long     placebo  0.6870 0.2658     0.2658     0.3126     2         
74          BZD-long   BZD-short -0.3055 0.3181     0.3181     0.3580     2         
77       eszopiclone     placebo  0.6503 0.1286     0.1286     0.2087     2         
80           placebo    zolpidem -1.1824 0.6258     0.6258     0.6470     2         
81           placebo    zolpidem -1.1706 0.6248     0.6248     0.6461     2         
100        melatonin     placebo  0.1894 0.1894     0.1894     0.2508     2         
104         BZD-long     placebo  0.7143 0.2757     0.2757     0.3209     2         
119          placebo    zolpidem -0.1815 0.2988     0.2988     0.3411     2         
120      eszopiclone     placebo  0.3387 0.1392     0.1392     0.2154     2         
127          placebo   ramelteon -0.1953 0.0651     0.0651     0.1768     2         
129        melatonin     placebo  0.1351 0.1096     0.1096     0.1976     2         
130        melatonin     placebo  0.2146 0.0746     0.0746     0.1805     2         
136      eszopiclone     placebo  0.7984 0.0760     0.0760     0.1811     2         
137          placebo    zolpidem -0.4431 0.1440     0.1440     0.2186     2         
143 BZD-intermediate   BZD-short -0.1607 0.1293     0.1293     0.2092     2         
145          placebo   ramelteon -0.1428 0.1219     0.1219     0.2047     2         
162          placebo  quetiapine -0.0506 0.5564     0.5564     0.5802     2         
164 BZD-intermediate mirtazapine -0.3261 0.2374     0.2374     0.2887     2         

Number of treatment arms (by study):
    narms
4       2
5       3
6       2
9       2
24      2
32      3
34      2
36      2
44      2
48      2
50      2
60      2
70      2
72      3
73      2
74      2
77      2
80      2
81      2
100     2
104     2
119     2
120     2
127     2
129     2
130     2
136     2
137     2
143     2
145     2
162     2
164     2

Results (fixed effects model):

              treat1      treat2     SMD             95%-CI    Q leverage
4           BZD-long   BZD-short -0.2755 [-0.5556;  0.0047] 0.01     0.31
5            placebo    zolpidem -0.4306 [-0.5738; -0.2875] 0.01        .
5           zaleplon    zolpidem -0.2303 [-0.3598; -0.1009] 0.23        .
5            placebo    zaleplon -0.2003 [-0.3445; -0.0560] 0.38        .
6        eszopiclone     placebo  0.6138 [ 0.5133;  0.7143] 4.18     0.25
9          BZD-short   zopiclone  0.1218 [-0.1540;  0.3976] 0.24     0.25
24         BZD-short     placebo  0.8985 [ 0.6648;  1.1321] 0.82     0.14
32           placebo    zaleplon -0.2003 [-0.3445; -0.0560] 2.81        .
32          zaleplon    zolpidem -0.2303 [-0.3598; -0.1009] 0.26        .
32           placebo    zolpidem -0.4306 [-0.5738; -0.2875] 0.62        .
34           placebo   zopiclone -0.7767 [-0.9583; -0.5951] 0.03     0.91
36  BZD-intermediate     placebo  0.7265 [ 0.5127;  0.9404] 0.03     0.46
44  BZD-intermediate     placebo  0.7265 [ 0.5127;  0.9404] 4.80     0.15
48          zaleplon    zolpidem -0.2303 [-0.3598; -0.1009] 0.88     0.24
50  BZD-intermediate    zolpidem  0.2959 [ 0.0479;  0.5439] 9.09     0.16
60           doxepin     placebo  0.4235 [ 0.0730;  0.7740] 0.00     1.00
70         melatonin     placebo  0.1667 [ 0.0536;  0.2798] 4.50     0.03
72          BZD-long   BZD-short -0.2755 [-0.5556;  0.0047] 0.30        .
72         BZD-short     placebo  0.8985 [ 0.6648;  1.1321] 3.23        .
72          BZD-long     placebo  0.6230 [ 0.3467;  0.8993] 1.55        .
73          BZD-long     placebo  0.6230 [ 0.3467;  0.8993] 0.06     0.28
74          BZD-long   BZD-short -0.2755 [-0.5556;  0.0047] 0.01     0.20
77       eszopiclone     placebo  0.6138 [ 0.5133;  0.7143] 0.08     0.16
80           placebo    zolpidem -0.4306 [-0.5738; -0.2875] 1.44     0.01
81           placebo    zolpidem -0.4306 [-0.5738; -0.2875] 1.40     0.01
100        melatonin     placebo  0.1667 [ 0.0536;  0.2798] 0.01     0.09
104         BZD-long     placebo  0.6230 [ 0.3467;  0.8993] 0.11     0.26
119          placebo    zolpidem -0.4306 [-0.5738; -0.2875] 0.70     0.06
120      eszopiclone     placebo  0.6138 [ 0.5133;  0.7143] 3.91     0.14
127          placebo   ramelteon -0.1837 [-0.2963; -0.0710] 0.03     0.78
129        melatonin     placebo  0.1667 [ 0.0536;  0.2798] 0.08     0.28
130        melatonin     placebo  0.1667 [ 0.0536;  0.2798] 0.41     0.60
136      eszopiclone     placebo  0.6138 [ 0.5133;  0.7143] 5.90     0.46
137          placebo    zolpidem -0.4306 [-0.5738; -0.2875] 0.01     0.26
143 BZD-intermediate   BZD-short -0.1720 [-0.3859;  0.0419] 0.01     0.71
145          placebo   ramelteon -0.1837 [-0.2963; -0.0710] 0.11     0.22
162          placebo  quetiapine -0.0506 [-1.1412;  1.0400] 0.00     1.00
164 BZD-intermediate mirtazapine -0.3261 [-0.7913;  0.1391] 0.00     1.00

Results (random effects model):

              treat1      treat2     SMD             95%-CI
4           BZD-long   BZD-short -0.2715 [-0.6004;  0.0574]
5            placebo    zolpidem -0.4826 [-0.6914; -0.2737]
5           zaleplon    zolpidem -0.2482 [-0.4682; -0.0282]
5            placebo    zaleplon -0.2344 [-0.4774;  0.0086]
6        eszopiclone     placebo  0.5641 [ 0.3697;  0.7585]
9          BZD-short   zopiclone  0.1333 [-0.2584;  0.5250]
24         BZD-short     placebo  0.8827 [ 0.5858;  1.1796]
32           placebo    zaleplon -0.2344 [-0.4774;  0.0086]
32          zaleplon    zolpidem -0.2482 [-0.4682; -0.0282]
32           placebo    zolpidem -0.4826 [-0.6914; -0.2737]
34           placebo   zopiclone -0.7494 [-1.0812; -0.4176]
36  BZD-intermediate     placebo  0.7117 [ 0.4288;  0.9947]
44  BZD-intermediate     placebo  0.7117 [ 0.4288;  0.9947]
48          zaleplon    zolpidem -0.2482 [-0.4682; -0.0282]
50  BZD-intermediate    zolpidem  0.2291 [-0.1024;  0.5606]
60           doxepin     placebo  0.4235 [-0.0526;  0.8996]
70         melatonin     placebo  0.1139 [-0.1054;  0.3332]
72          BZD-long   BZD-short -0.2715 [-0.6004;  0.0574]
72         BZD-short     placebo  0.8827 [ 0.5858;  1.1796]
72          BZD-long     placebo  0.6112 [ 0.2866;  0.9359]
73          BZD-long     placebo  0.6112 [ 0.2866;  0.9359]
74          BZD-long   BZD-short -0.2715 [-0.6004;  0.0574]
77       eszopiclone     placebo  0.5641 [ 0.3697;  0.7585]
80           placebo    zolpidem -0.4826 [-0.6914; -0.2737]
81           placebo    zolpidem -0.4826 [-0.6914; -0.2737]
100        melatonin     placebo  0.1139 [-0.1054;  0.3332]
104         BZD-long     placebo  0.6112 [ 0.2866;  0.9359]
119          placebo    zolpidem -0.4826 [-0.6914; -0.2737]
120      eszopiclone     placebo  0.5641 [ 0.3697;  0.7585]
127          placebo   ramelteon -0.1729 [-0.4351;  0.0894]
129        melatonin     placebo  0.1139 [-0.1054;  0.3332]
130        melatonin     placebo  0.1139 [-0.1054;  0.3332]
136      eszopiclone     placebo  0.5641 [ 0.3697;  0.7585]
137          placebo    zolpidem -0.4826 [-0.6914; -0.2737]
143 BZD-intermediate   BZD-short -0.1710 [-0.4850;  0.1431]
145          placebo   ramelteon -0.1729 [-0.4351;  0.0894]
162          placebo  quetiapine -0.0506 [-1.1878;  1.0866]
164 BZD-intermediate mirtazapine -0.3261 [-0.8920;  0.2398]

Number of studies: k = 32
Number of pairwise comparisons: m = 38
Number of observations: o = 7111
Number of treatments: n = 13
Number of designs: d = 18

Fixed effects model

Treatment estimate (sm = 'SMD', comparison: other treatments vs 'placebo'):
                    SMD            95%-CI     z  p-value
BZD-intermediate 0.7265 [ 0.5127; 0.9404]  6.66 < 0.0001
BZD-long         0.6230 [ 0.3467; 0.8993]  4.42 < 0.0001
BZD-short        0.8985 [ 0.6648; 1.1321]  7.54 < 0.0001
doxepin          0.4235 [ 0.0730; 0.7740]  2.37   0.0179
eszopiclone      0.6138 [ 0.5133; 0.7143] 11.97 < 0.0001
melatonin        0.1667 [ 0.0536; 0.2798]  2.89   0.0039
mirtazapine      1.0526 [ 0.5406; 1.5646]  4.03 < 0.0001
placebo               .                 .     .        .
quetiapine       0.0506 [-1.0400; 1.1412]  0.09   0.9275
ramelteon        0.1837 [ 0.0710; 0.2963]  3.20   0.0014
zaleplon         0.2003 [ 0.0560; 0.3445]  2.72   0.0065
zolpidem         0.4306 [ 0.2875; 0.5738]  5.90 < 0.0001
zopiclone        0.7767 [ 0.5951; 0.9583]  8.38 < 0.0001

Random effects model

Treatment estimate (sm = 'SMD', comparison: other treatments vs 'placebo'):
                    SMD            95%-CI    z  p-value            95%-PI
BZD-intermediate 0.7117 [ 0.4288; 0.9947] 4.93 < 0.0001 [ 0.2580; 1.1654]
BZD-long         0.6112 [ 0.2866; 0.9359] 3.69   0.0002 [ 0.1273; 1.0952]
BZD-short        0.8827 [ 0.5858; 1.1796] 5.83 < 0.0001 [ 0.4191; 1.3463]
doxepin          0.4235 [-0.0526; 0.8996] 1.74   0.0813 [-0.1848; 1.0317]
eszopiclone      0.5641 [ 0.3697; 0.7585] 5.69 < 0.0001 [ 0.1659; 0.9623]
melatonin        0.1139 [-0.1054; 0.3332] 1.02   0.3086 [-0.2985; 0.5263]
mirtazapine      1.0378 [ 0.4051; 1.6705] 3.21   0.0013 [ 0.2865; 1.7891]
placebo               .                 .    .        .                 .
quetiapine       0.0506 [-1.0866; 1.1878] 0.09   0.9305 [-1.2000; 1.3013]
ramelteon        0.1729 [-0.0894; 0.4351] 1.29   0.1964 [-0.2667; 0.6125]
zaleplon         0.2344 [-0.0086; 0.4774] 1.89   0.0587 [-0.1926; 0.6614]
zolpidem         0.4826 [ 0.2737; 0.6914] 4.53 < 0.0001 [ 0.0763; 0.8889]
zopiclone        0.7494 [ 0.4176; 1.0812] 4.43 < 0.0001 [ 0.2600; 1.2388]

Quantifying heterogeneity / inconsistency:
tau^2 = 0.0270; tau = 0.1644; I^2 = 52.4% [24.1%; 70.1%]

Tests of heterogeneity (within designs) and inconsistency (between designs):
                    Q d.f. p-value
Total           48.28   23  0.0015
Within designs  29.63   15  0.0133
Between designs 18.65    8  0.0169
[1] "A total of 13 treatments are included in the network."
[1] "A total of 32 studies are included in this analysis."
[1] "Estimated heterogeneity tau-squared0.03"
[1] "Global test for inconsistency, p-value 0.01688 (Q=19, d.o.f. 8)"
[1] "File created on 2022-04-11"
